Literature DB >> 19736241

Considering health insurance: how do dialysis initiates with Medicaid coverage differ from persons without Medicaid coverage?

James B Wetmore1, Sally K Rigler, Jonathan D Mahnken, Purna Mukhopadhyay, Theresa I Shireman.   

Abstract

BACKGROUND: Type of health insurance is an important mediator of medical outcomes in the United States. Medicaid, a jointly sponsored Federal/State programme, is designed to serve medically needy individuals. How these patients differ from non-Medicaid-enrolled incident dialysis patients and how these differences have changed over time have not been systematically examined.
METHODS: Using data from the United States Renal Data System, we identified individuals initiating dialysis from 1995 to 2004 and categorized their health insurance status. Longitudinal trends in demographic, risk behaviour, functional, comorbidity, laboratory and dialysis modality factors, as reported on the Medical Evidence Form (CMS-2728), were examined in all insurance groups. Polychotomous logistic regression was used to estimate adjusted generalized ratios (AGRs) for these factors by insurance status, with Medicaid as the referent insurance group.
RESULTS: Overall, males constitute a growing percentage of both Medicaid and non-Medicaid patients, but in contrast to other insurance groups, Medicaid has a higher proportion of females. Non-Caucasians also constitute a higher proportion of Medicaid patients than non-Medicaid patients. Body mass index increased in all groups over time, and all groups witnessed a significant decrease in initiation on peritoneal dialysis. Polychotomous regression showed generally lower AGRs for minorities, risk behaviours and functional status, and higher AGRs for males, employment and self-care dialysis, for non-Medicaid insurance relative to Medicaid.
CONCLUSIONS: While many broad parallel trends are evident in both Medicaid and non-Medicaid incident dialysis patients, many important differences between these groups exist. These findings could have important implications for policy planners, providers and payers.

Entities:  

Mesh:

Year:  2009        PMID: 19736241      PMCID: PMC2910325          DOI: 10.1093/ndt/gfp396

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  32 in total

Review 1.  Guidelines for healthy weight.

Authors:  W C Willett; W H Dietz; G A Colditz
Journal:  N Engl J Med       Date:  1999-08-05       Impact factor: 91.245

Review 2.  Peritoneal dialysis in Europe: an analysis of its rise and fall.

Authors:  Norbert Lameire; Patrick Peeters; Raymond Vanholder; Wim Van Biesen
Journal:  Blood Purif       Date:  2006       Impact factor: 2.614

3.  Excerpts from the United States Renal Data System 2004 annual data report: atlas of end-stage renal disease in the United States.

Authors:  Allan J Collins; Bertram Kasiske; Charles Herzog; Blanche Chavers; Robert Foley; David Gilbertson; Richard Grimm; Jiannong Liu; Thomas Louis; Willard Manning; Arthur Matas; Marshall McBean; Anne Murray; Wendy St Peter; Jay Xue; Qiao Fan; Haifeng Guo; Shuling Li; Suying Li; Tricia Roberts; Jon Snyder; Craig Solid; Changchun Wang; Eric Weinhandl; Cheryl Arko; Shu-Cheng Chen; Frederick Dalleska; Frank Daniels; Stephan Dunning; James Ebben; Eric Frazier; Roger Johnson; Daniel Sheets; Beth Forrest; Delaney Berrini; Edward Constantini; Susan Everson; Pamela Frederick; Paul Eggers; Lawrence Agodoa
Journal:  Am J Kidney Dis       Date:  2005-01       Impact factor: 8.860

4.  Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients.

Authors:  Deborah L Regidor; Joel D Kopple; Csaba P Kovesdy; Ryan D Kilpatrick; Charles J McAllister; Jason Aronovitz; Sander Greenland; Kamyar Kalantar-Zadeh
Journal:  J Am Soc Nephrol       Date:  2006-04       Impact factor: 10.121

5.  The American health care system--Medicaid.

Authors:  J K Iglehart
Journal:  N Engl J Med       Date:  1999-02-04       Impact factor: 91.245

Review 6.  Metabolic syndrome and chronic kidney disease.

Authors:  B Ching-Ha Kwan; S Beddhu
Journal:  Minerva Urol Nefrol       Date:  2006-03       Impact factor: 3.720

7.  Prevalence of overweight and obesity in the United States, 1999-2004.

Authors:  Cynthia L Ogden; Margaret D Carroll; Lester R Curtin; Margaret A McDowell; Carolyn J Tabak; Katherine M Flegal
Journal:  JAMA       Date:  2006-04-05       Impact factor: 56.272

Review 8.  Healthcare systems and end-stage renal disease (ESRD) therapies--an international review: access to ESRD treatments.

Authors:  W H Hörl; F de Alvaro; P F Williams
Journal:  Nephrol Dial Transplant       Date:  1999       Impact factor: 5.992

9.  Expanding public health insurance to parents: effects on children's coverage under Medicaid.

Authors:  Lisa Dubay; Genevieve Kenney
Journal:  Health Serv Res       Date:  2003-10       Impact factor: 3.402

Review 10.  Kidney disease in the Hispanic population: facing the growing challenge.

Authors:  Julio E Benabe; Elena V Rios
Journal:  J Natl Med Assoc       Date:  2004-06       Impact factor: 1.798

View more
  16 in total

1.  Early outcomes among those initiating chronic dialysis in the United States.

Authors:  Kevin E Chan; Frank W Maddux; Nina Tolkoff-Rubin; S Ananth Karumanchi; Ravi Thadhani; Raymond M Hakim
Journal:  Clin J Am Soc Nephrol       Date:  2011-09-29       Impact factor: 8.237

2.  Race, ethnicity, and state-by-state geographic variation in hemorrhagic stroke in dialysis patients.

Authors:  James B Wetmore; Milind A Phadnis; Jonathan D Mahnken; Edward F Ellerbeck; Sally K Rigler; Xinhua Zhou; Theresa I Shireman
Journal:  Clin J Am Soc Nephrol       Date:  2014-01-23       Impact factor: 8.237

3.  Impact of race on cumulative exposure to antihypertensive medications in dialysis.

Authors:  James B Wetmore; Jonathan D Mahnken; Sally K Rigler; Edward F Ellerbeck; Purna Mukhopadhyay; Qingjiang Hou; Theresa I Shireman
Journal:  Am J Hypertens       Date:  2012-12-28       Impact factor: 2.689

4.  Association of race with cumulative exposure to statins in dialysis.

Authors:  James B Wetmore; Jonathan D Mahnken; Sally K Rigler; Edward F Ellerbeck; Purna Mukhopadhyay; Qingjiang Hou; Theresa I Shireman
Journal:  Am J Nephrol       Date:  2012-06-27       Impact factor: 3.754

5.  Comparative Effectiveness of Renin-Angiotensin System Antagonists in Maintenance Dialysis Patients.

Authors:  Theresa I Shireman; Jonathan D Mahnken; Milind A Phadnis; Edward F Ellerbeck; James B Wetmore
Journal:  Kidney Blood Press Res       Date:  2016-11-21       Impact factor: 2.687

6.  The prevalence of and factors associated with chronic atrial fibrillation in Medicare/Medicaid-eligible dialysis patients.

Authors:  James B Wetmore; Jonathan D Mahnken; Sally K Rigler; Edward F Ellerbeck; Purna Mukhopadhyay; John A Spertus; Qingjiang Hou; Theresa I Shireman
Journal:  Kidney Int       Date:  2011-12-21       Impact factor: 10.612

7.  Neighborhood socioeconomic status, race, and mortality in young adult dialysis patients.

Authors:  Tanya S Johns; Michelle M Estrella; Deidra C Crews; Lawrence J Appel; Cheryl A M Anderson; Patti L Ephraim; Courtney Cook; L Ebony Boulware
Journal:  J Am Soc Nephrol       Date:  2014-06-12       Impact factor: 10.121

8.  Relationship between calcium channel blocker class and mortality in dialysis.

Authors:  James B Wetmore; Jonathan D Mahnken; Milind A Phadnis; Edward F Ellerbeck; Theresa I Shireman
Journal:  Pharmacoepidemiol Drug Saf       Date:  2015-09-15       Impact factor: 2.890

9.  Geographic variation in cardioprotective antihypertensive medication usage in dialysis patients.

Authors:  James B Wetmore; Jonathan D Mahnken; Purna Mukhopadhyay; Qingjiang Hou; Edward F Ellerbeck; Sally K Rigler; John A Spertus; Theresa I Shireman
Journal:  Am J Kidney Dis       Date:  2011-05-31       Impact factor: 8.860

10.  Atrial fibrillation and risk of stroke in dialysis patients.

Authors:  James B Wetmore; Edward F Ellerbeck; Jonathan D Mahnken; Milind Phadnis; Sally K Rigler; Purna Mukhopadhyay; John A Spertus; Xinhua Zhou; Qingjiang Hou; Theresa I Shireman
Journal:  Ann Epidemiol       Date:  2013-01-16       Impact factor: 3.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.